Hyperparathyroidism, Secondary
"Hyperparathyroidism, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.
| Descriptor ID |
D006962
|
| MeSH Number(s) |
C19.642.355.480
|
| Concept/Terms |
Hyperparathyroidism, Secondary- Hyperparathyroidism, Secondary
- Secondary Hyperparathyroidism
- Hyperparathyroidisms, Secondary
- Secondary Hyperparathyroidisms
|
Below are MeSH descriptors whose meaning is more general than "Hyperparathyroidism, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Hyperparathyroidism, Secondary".
This graph shows the total number of publications written about "Hyperparathyroidism, Secondary" by people in this website by year, and whether "Hyperparathyroidism, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperparathyroidism, Secondary" by people in Profiles.
-
Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation. Am J Kidney Dis. 2024 01; 83(1):58-70.
-
Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years?. Clin Nephrol. 2019 Dec; 92(6):279-286.
-
Preoperative calcitriol reduces postoperative intravenous calcium requirements and length of stay in parathyroidectomy for renal-origin hyperparathyroidism. Surgery. 2019 01; 165(1):151-157.
-
Rates of secondary hyperparathyroidism after bypass operation for super-morbid obesity: An overlooked phenomenon. Surgery. 2017 03; 161(3):720-726.
-
In experimental chronic kidney disease or cancer, parathyroid hormone is a novel mediator of cachexia. Kidney Int. 2016 May; 89(5):973-975.
-
Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort. Pediatr Nephrol. 2016 Jan; 31(1):121-9.
-
Leontiasis ossea caused by long-standing hyperparathyroidism secondary to chronic renal failure. Surgery. 2014 Dec; 156(6):1644-6.
-
Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf. 2012 Nov; 21(11):1232-9.
-
Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. Eur J Heart Fail. 2012 Mar; 14(3):326-32.
-
Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study. Clin Nephrol. 2008 Oct; 70(4):319-24.